Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > Post DEAL Interview

<< Previous

Bullboard Posts

Next >>

Post by 24minus7on Jun 14, 2022 5:54am

315 Views

Post# 34754214

Post DEAL Interview

https://57ea05b9-8ae7-4fa0-b2d8-87d70d135d8c.usrfiles.com/ugd/57ea05_e067cb96589a468c806b109903079c43.pdf Lets talk numbers. Can you elaborate on the actual figures? HV: Do you see this smile on my face? I can assure everyone that AbbVie is rewarding Sirona Biochem appropriately for our breakthrough technology. Although I am contractually bound to not comment on how much we are receiving, suffice it to say that it will be substantial given that we are getting royalty payments on the global sales of AbbVies products based on our patents. AbbVie has an agreement that allows them to commercialize and market TFC-1067 worldwide into their established global network.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec